173 related articles for article (PubMed ID: 38034543)
1. Evaluation of proteolytic activity and serine proteases distribution in plasma from patients with bladder cancer.
Synelnyk T; Vovk T; Halenova T; Tytarenko V; Raksha N; Savchuk O; Falalyeyeva T; Ostapchenko L; Yakovlev P; Kozyk M; Thorley D; Strubchevska K
Front Med (Lausanne); 2023; 10():1276882. PubMed ID: 38034543
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Csiszar A; Kutay B; Wirth S; Schmidt U; Macho-Maschler S; Schreiber M; Alacakaptan M; Vogel GF; Aumayr K; Huber LA; Beug H
Breast Cancer Res; 2014 Sep; 16(5):433. PubMed ID: 25212966
[TBL] [Abstract][Full Text] [Related]
3. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.
Liotta LA; Goldfarb RH; Brundage R; Siegal GP; Terranova V; Garbisa S
Cancer Res; 1981 Nov; 41(11 Pt 1):4629-36. PubMed ID: 6458354
[TBL] [Abstract][Full Text] [Related]
4. Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma.
Mehner C; Hockla A; Coban M; Madden B; Estrada R; Radisky DC; Radisky ES
J Biol Chem; 2022 Aug; 298(8):102146. PubMed ID: 35716777
[TBL] [Abstract][Full Text] [Related]
5. Proteolytic modification of insulin-like growth factor-binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes.
Frost VJ; Macaulay VM; Wass JA; Holly JM
J Endocrinol; 1993 Sep; 138(3):545-54. PubMed ID: 7506292
[TBL] [Abstract][Full Text] [Related]
6. Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins: high affinity binding of plasminogen to IGF-II and IGF-binding protein-3.
Oesterreicher S; Blum WF; Schmidt B; Braulke T; Kübler B
J Biol Chem; 2005 Mar; 280(11):9994-10000. PubMed ID: 15642732
[TBL] [Abstract][Full Text] [Related]
7. Contribution of proteases and plasmin-acquired activity in migration of Peptostreptococcus micros through a reconstituted basement membrane.
Grenier D; Bouclin R
Oral Microbiol Immunol; 2006 Oct; 21(5):319-25. PubMed ID: 16922932
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis of insulin-like growth factor binding proteins by a novel 50-kilodalton metalloproteinase in human pregnancy serum.
Kübler B; Cowell S; Zapf J; Braulke T
Endocrinology; 1998 Apr; 139(4):1556-63. PubMed ID: 9528934
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Schmitt M; Jänicke F; Moniwa N; Chucholowski N; Pache L; Graeff H
Biol Chem Hoppe Seyler; 1992 Jul; 373(7):611-22. PubMed ID: 1515091
[TBL] [Abstract][Full Text] [Related]
10. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
11. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.
Rønne E; Pappot H; Grøndahl-Hansen J; Høyer-Hansen G; Plesner T; Hansen NE; Danø K
Br J Haematol; 1995 Mar; 89(3):576-81. PubMed ID: 7734357
[TBL] [Abstract][Full Text] [Related]
12. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
Müllertz S
Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.
Skrzydlewska E; Sulkowska M; Koda M; Sulkowski S
World J Gastroenterol; 2005 Mar; 11(9):1251-66. PubMed ID: 15761961
[TBL] [Abstract][Full Text] [Related]
14. Oxidative inactivation of plasmin and other serine proteases by copper and ascorbate.
Lind SE; McDonagh JR; Smith CJ
Blood; 1993 Sep; 82(5):1522-31. PubMed ID: 8364203
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of neutral proteases present in inflamed human gingiva.
Suomalainen K; Sorsa T; Uitto VJ; Vauhkonen M; Lindy S
Scand J Dent Res; 1989 Aug; 97(4):346-54. PubMed ID: 2552568
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
17. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer.
Netzel-Arnett S; Hooper JD; Szabo R; Madison EL; Quigley JP; Bugge TH; Antalis TM
Cancer Metastasis Rev; 2003; 22(2-3):237-58. PubMed ID: 12784999
[TBL] [Abstract][Full Text] [Related]
18. Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage.
Poon IK; Olsson AK; Hulett MD; Parish CR
Biochem J; 2009 Oct; 424(1):27-37. PubMed ID: 19712047
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
Persky B; Ostrowski LE; Pagast P; Ahsan A; Schultz RM
Cancer Res; 1986 Aug; 46(8):4129-34. PubMed ID: 3524801
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored
Herranz R; Oto J; Hueso M; Plana E; Cana F; Castaño M; Cordón L; Ramos-Soler D; Bonanad S; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
Front Immunol; 2023; 14():1171065. PubMed ID: 37275882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
